Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of Combined Progression Index (CPI) in 132 patients with unresectable peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy.

Human pathology·2026
Same author

Enhanced recovery after surgery for gastric cancer with HIPEC: feasibility and outcomes in a complex setting.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Explainable AI-based analysis of human pancreas sections identifies traits of type 2 diabetes.

Nature communications·2026
Same author

The dangerous liaisons between central venous stents and catheters: a case report.

The journal of vascular access·2026
Same author

Preoperative EUS-guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study.

Endoscopic ultrasound·2026
Same author

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal for immunotherapy of cancer·2026
Same journal

Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress.

Pleura and peritoneum·2026
Same journal

Preoperative chemotherapy in colorectal peritoneal metastatic disease - a real-world observational cohort study.

Pleura and peritoneum·2026
Same journal

The utility of a pleural carcinomatosis score for assessing resectability.

Pleura and peritoneum·2026
Same journal

Proposed strategy after complete LAMN (low-grade appendiceal mucinous neoplasm) resection by different RENAPE units: need for a new consensus?

Pleura and peritoneum·2026
Same journal

High prevalence of <i>KRAS</i> and <i>GNAS</i> mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategies.

Pleura and peritoneum·2026
Same journal

Assessing data completeness in the international society for the study of pleura and peritoneum (ISSPP) PIPAC database: a multicenter evaluation from 2020-2024.

Pleura and peritoneum·2025
See all related articles

Related Experiment Video

Updated: Jul 7, 2025

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.3K

Second annual report from the ISSPP PIPAC database.

Michael Bau Mortensen1, Francesco Casella2, Özgül Düzgün3

  • 1Upper GI and HPB Section, Department of Surgery, Odense Universitetshospital, Odense, Denmark.

Pleura and Peritoneum
|December 25, 2023
PubMed
Summary
This summary is machine-generated.

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) shows promising results for peritoneal metastasis (PM). Real-world data from the ISSPP PIPAC database supports its use, with significant histological response rates and variable survival outcomes based on cancer type.

Keywords:
ISSPPPIPACdatabaseperitoneal metastasis

More Related Videos

The ITS2 Database
16:17

The ITS2 Database

Published on: March 12, 2012

30.9K
Automated Sample Multiplexing by using Combined Precursor Isotopic Labeling and Isobaric Tagging cPILOT
09:24

Automated Sample Multiplexing by using Combined Precursor Isotopic Labeling and Isobaric Tagging cPILOT

Published on: December 18, 2020

5.6K

Related Experiment Videos

Last Updated: Jul 7, 2025

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.3K
The ITS2 Database
16:17

The ITS2 Database

Published on: March 12, 2012

30.9K
Automated Sample Multiplexing by using Combined Precursor Isotopic Labeling and Isobaric Tagging cPILOT
09:24

Automated Sample Multiplexing by using Combined Precursor Isotopic Labeling and Isobaric Tagging cPILOT

Published on: December 18, 2020

5.6K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Peritoneal metastasis (PM) presents a significant challenge in cancer treatment.
  • Systemic chemotherapy has limited efficacy for PM.
  • Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) offers a targeted approach.

Purpose of the Study:

  • To evaluate the real-world outcomes of PIPAC-directed therapy for patients with PM.
  • To analyze data from the International Society for the Study of the Pleura and Peritoneum (ISSPP) PIPAC database.

Main Methods:

  • Analysis of data from 809 patients with PM across 12 centers between June 2020 and February 2023.
  • 2,456 PIPAC procedures were performed, with a focus on response rates, adverse events, and survival.

Main Results:

  • High rates of histological response (PRGS≤2 in 80%) were observed, particularly by the third PIPAC.
  • Low rates of serious complications (grade ≥3b: 22%) and adverse events (grade ≥3: 8%).
  • Median overall survival varied by primary tumor, from 10.7 months (gastric cancer) to 27.1 months (mesothelioma).

Conclusions:

  • The ISSPP PIPAC database provides robust real-world evidence supporting PIPAC therapy for PM.
  • PIPAC demonstrates efficacy in improving histological response and offers survival benefits for various primary tumors.